Association between prostate-specific antigen and leptin, adiponectin, HbA1c or C-peptide among African-American and Caucasian men

Prostate Cancer and Prostatic Diseases

Volumn 11, Issue 3, 2008, Pages 264-269

  Fowke, J H ^a   Matthews, C M ^a   Buchowski, M S ^a   Signorello, L B ^a,b   Chang, S S ^a   Cookson, M S ^a   Blot, W J ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b INTERNATIONAL EPIDEMIOLOGY INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; C PEPTIDE; HEMOGLOBIN A1C; LEPTIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC VALUE; DISEASE MARKER; HEMOGLOBIN BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE;

ADIPONECTIN; ADULT; AFRICAN AMERICANS; AGED; BODY MASS INDEX; C-PEPTIDE; COHORT STUDIES; DIABETES COMPLICATIONS; EARLY DIAGNOSIS; EUROPEAN CONTINENTAL ANCESTRY GROUP; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LEPTIN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 50649085199     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4501022     Document Type: Article

References (55)

1. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006; 295: 1549-1555.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-130.
3. Ribeiro R, Lopes C, Medeiros R. The link between obesity and prostate cancer: The leptin pathway and therapeutic perspectives. Prostate Cancer Prostatic Dis 2006; 9: 19-24.
4. Andersson S-O, Wolk A, Bergstrom R, Adami H-O, Engholm G, Englund A et al. Body size and prostate cancer: A 20-year follow-up study among 135006 Swedish construction workers. J Natl Cancer Inst 1997; 89: 385-389.
5. Rodriguez C, Patel AV, Calle EE, Jacobs EJ, Chao A, Thun MJ. Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev 2001; 10: 345-353.
6. Snowdon D, Phillips R, Choi W. Diet, obesity and risk of fatal prostate cancer. Am J Epidemiol 1984; 120: 244-250.
7. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 2003; 348: 1625.
8. Freedland SJ, Aronson WJ, Kane CJ, Presti Jr JC, Amling CL, Elashoff D et al. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: A report by the Shared Equal Access Regional Cancer Hospital Database Study Group. J Clin Oncol 2004; 22: 446-453.
9. Strom SS, Wang X, Pettaway CA, Logothetis CJ, Yamamura Y, Do KA et al. Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res 2005; 11: 6889-6894.
10. Bassett WW, Cooperberg MR, Sadetsky N, Silva S, DuChane J, Pasta DJ et al. Impact of obesity on prostate cancer recurrence after radical prostatectomy: Data from CaPSURE. Urology 2005; 66: 1060-1065.
11. Freedland S, Giovannucci E, Platz E. Are findings from studies of obesity and prostate cancer really in conflict? Cancer Causes Control 2006; 17: 5-9.
12. MacInnis R, English D. Body size and composition and prostate cancer risk: Systematic review and meta-regression analysis. Cancer Causes Control 2006; 17: 989-1003.
13. Laukkanen JA, Laaksonen DE, Niskanen L, Pukkala E, Hakkarainen A, Salonen JT. Metabolic syndrome and the risk of prostate cancer in Finnish men: A population-based study. Cancer Epidemiol Biomarkers Prev 2004; 13: 1646-1650.
14. Lund Haheim L, Wisloff TF, Holme I, Nafstad P. Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am J Epidemiol 2006; 164: 769-774.
15. von Hafe P, Pina F, Perez A, Tavares M, Barros H. Visceral fat accumulation as a risk factor for prostate cancer. Obes Res 2004; 12: 1930-1935.
16. Chang S, Hursting SD, Contois JH, Strom SS, Yamamura Y, Babaian RJ et al. Leptin and prostate cancer. Prostate 2001; 46: 62-67.
17. Stattin P, Soderberg S, Hallmans G, Bylund A, Kaaks R, Bergh A et al. Leptin is associated with increased prostate cancer risk: A nested case-referent study. J Clin Endocrinol Metab 2001; 86: 1341-1345.
18. Saglam K, Aydur E, Yilmaz M, Goktas S. Leptin influences cellular differentiation and progression in prostate cancer. J Urol 2003; 169: 1308-1311.
19. Hsing AW, Gao YT, Chua Jr S, Deng J, Stanczyk FZ. Insulin resistance and prostate cancer risk. J Natl Cancer Inst 2003; 95: 67-71.
20. Hammarsten J, Hogstedt B. Hyperinsulinaemia: A prospective risk factor for lethal clinical prostate cancer. Eur J Cancer 2005; 41: 2887-2895.
21. Wright ME, Chang SC, Schatzkin A, Albanes D, Kipnis V, Mouw T et al. Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer 2007; 109: 675-684.
22. Tande AJ, Platz EA, Folsom AR. The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol 2006; 164: 1094-1102.
23. Porter MP, Stanford JL. Obesity and the risk of prostate cancer. Prostate 2005; 62: 316-321.
24. Bradbury BD, Wilk JB, Kaye JA. Obesity and the risk of prostate cancer (United States). Cancer Causes Control 2005; 16: 637-641.
25. Lagiou P, Signorello LB, Trichopoulos D, Tzonou A, Trichopoulou A, Mantzoros CS. Leptin in relation to prostate cancer and benign prostatic hyperplasia. Int J Cancer 1998; 76: 25-28.
26. Stattin P, Kaaks R, Johansson R, Gislefoss R, Soderberg S, Alfthan H et al. Plasma leptin is not associated with prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2003; 12: 474-475.
27. Hsing AW, Chua S, Gao Y-T, Gentzschein E, Chang L, Deng J et al. Prostate cancer risk and serum levels of insulin and leptin: A population based-study. J Natl Cancer Inst 2001; 93: 783-791.
28. Gong Z, Neuhouser ML, Goodman PJ, Albanes D, Chi C, Hsing AW et al. Obesity, diabetes, and risk of prostate cancer: Results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 2006; 15: 1977-1983.
29. Littman AJ, White E, Kristal AR. Anthropometrics and prostate cancer risk. Am J Epidemiol 2007; 165: 1271-1279.
30. Rodriguez C, Freedland SJ, Deka A, Jacobs EJ, McCullough ML, Patel AV et al. Body mass index, weight change, and risk of prostate cancer in the cancer prevention study II nutrition cohort. Cancer Epidemiol Biomarkers Prev 2007; 16: 63-69.
31. Giovannucci E, Rimm E, Stampfer M, Colditz GA, Willett WC. Diabetes mellitus and risk of prostate cancer (United States). Cancer Causes Control 1998; 9: 3-9.
32. Rodriguez C, Patel AV, Mondul AM, Jacobs EJ, Thun MJ, Calle EE. Diabetes and risk of prostate cancer in a prospective cohort of US men. Am J Epidemiol 2005; 161: 147-152.
33. Velicer CM, Dublin S, White E. Diabetes and the risk of prostate cancer: the role of diabetes treatment and complications. Prostate Cancer Prostatic Dis 2006; 10: 46-51.
34. Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 2056-2062.
35. Fowke JH, Signorello LB, Chang SS, Matthews CE, Buchowski MS, Cookson MS et al. Effects of obesity and height on PSA and percent free PSA levels among African-American and Caucasian men. Cancer 2006; 107: 2361-2367.
36. Kristal AR, Chi C, Tangen C, Goodman PJ, Etzioni R, Thompson IM. Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase. Cancer 2005; 106: 320-328.
37. Baillargeon J, Pollock BH, Kristal AR, Bradshaw P, Hernandex J, Basler J et al. The association of body mass index and prostate-specific antigen in a population-based study. Cancer 2005; 103: 10920-11095.
38. Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen TP, Salonen R et al. Sex hormones, inflammation and the metabolic syndrome: A population-based study. Eur J Endocrinol 2003; 149: 601-608.
39. Philips GB, Jing T, Heymsfield SB. Relationships in men of sex hormones, insulin, adiposity, and risk factors for myocardial infarction. Metabolism 2003; 52: 784-790.
40. Svartberg J, von Muhlen D, Sundsfjord J, Jorde R. Waist circumference and testosterone levels in community dwelling men. The Tromso study. Eur J Epidemiol 2004; 19: 657-663.
41. Kaaks R, Lukanova A, Rinaldi S, Biessy C, Soderberg S, Olsson T et al. Interrelationships between plasma testosterone, SHBG, IGF-I, insulin and leptin in prostate cancer cases and controls. Eur J Cancer Prev 2003; 12: 309-315.
42. Gapstur SM, Gann PH, Kopp P, Colangelo L, Longcope C, Liu K. Serum androgen concentrations in young men: A longitudinal analysis of associations with age, obesity, and race. The CARDIA male hormone study. Cancer Epidemiol Biomarkers Prev 2002; 11: 1041-1047.
43. Freedland SJ, Sokoll LJ, Mangold La, Bruzek DJ, Mohr P, Yiu SK et al. Serum leptin and pathological findings at the time of radical prostatectomy. J Urol 2005; 173: 773-776.
44. Freedland SJ, Sokoll LJ, Platz EA, Mangold LA, Bruzek DJ, Mohr P et al. Association between serum adiponectin, and pathological stage and grade in men undergoing radical prostatectomy. J Urol 2005; 174 1266-1270.
45. Signorello LB, Hargreaves MK, Steinwandel MD, Zheng W, Cai Q, Schlundt DG et al. Southern community cohort study: Establishing a cohort to investigate health disparities. J Natl Med Assoc 2005; 97 972-979.
46. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: A systematic review and meta-analysis. JAMA 2006; 295: 1288-1299.
47. Oh JY, Barrett-Connor E, Wedick NM, Wingard DL. Endogenous sex hormones and the development of type 2 diabetes in older men and women: The Rancho Bernardo study. Diabetes Care 2002; 25: 55-60.
48. Muller M, Grobbee DE, den TI, Lamberts SW, van der Schouw YT. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab 2005; 90: 2618-2623.
49. Abate N, Haffner SM, Garg A, Peshock RM, Grundy SM. Sex steroid hormones, upper body obesity, and insulin resistance. J Clin Endocrinol Metab 2002; 87: 4522-4527.
50. Hammarsten J, Hogstedt B, Holthuis N, Mellstrom D. Components of the metabolic syndrome - risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1998; 1 157-162.
51. Dahle SE, Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Hsing AW. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 2002; 168: 599-604.
52. Parsons JK, Carter HB, Partin AW, Windham BG, Metter EJ, Ferrucci L et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 2006; 91: 2562-2568.
53. Fowke JH, Motley SS, Cookson MS, Concepcion R, Chang SS, Wills ML et al. The association between body size, prostate volume and prostate-specific antigen. Prostate Cancer Prostatic Dis 2006; 10: 137-142.
54. Saaddine JB, Fagot-Campagna A, Rolka D, Narayan KMV, Geiss L, Eberhardt M et al. Distribution of HbA1c levels for children and young adults in the US: Third National Health and Nutrition Examination Survey. Diabetes Care 2002; 25: 1326-1330.
55. Osei K, Schuster DP, Amoah AG, Owusu SK. Diabetes in Africa. Pathogenesis of type 1 and type 2 diabetes mellitus in sub-Saharan Africa: Implications for transitional populations. J Cardiovasc Risk 2003; 10: 85-96.